Skip to main content
×
Home

Noonan, Costello and cardio–facio–cutaneous syndromes: dysregulation of the Ras–MAPK pathway

  • William E. Tidyman (a1) and Katherine A. Rauen (a2) (a3)
Abstract

A class of developmental disorders caused by dysregulation of the Ras-induced mitogen-activated protein kinase (MAPK) cascade (the Ras–MAPK pathway) has emerged. Three of these disorders – Noonan, Costello and cardio–facio–cutaneous syndromes – have overlapping phenotypic features characterised by distinctive facial dysmorphia, cardiac defects, musculoskeletal and cutaneous abnormalities, and neurocognitive delay. The germline mutations associated with these disorders are in genes that encode proteins of the Ras–MAPK pathway. In vitro studies have determined that the overwhelming majority of these mutations result in increased signal transduction down the pathway, but usually to a lesser degree than somatic mutations in the same genes that are associated with cancer. The Ras–MAPK pathway is essential in the regulation of the cell cycle, differentiation, growth and senescence, so it is not surprising that germline mutations that affect its function have profound effects on development. Here we review the clinical consequences of the known molecular lesions associated with Noonan syndrome, Costello syndrome and cardio–facio–cutaneous syndrome, and explore possible therapeutic modalities for treatment.

Copyright
Corresponding author
*Corresponding author: Katherine A. Rauen, UCSF Helen Diller Family Comprehensive Cancer Center, 2340 Sutter Street, Room S429, Box 0128, San Francisco, CA 94115, USA. Tel: +1 415 514 3513; Fax: +1 415 502 3179; E-mail: rauenk@peds.ucsf.edu
References
Hide All
1Hancock J.F. (2003) Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 4, 373-384
2Bos J.L. (1989) ras oncogenes in human cancer: a review. Cancer Res 49, 4682-4689
3Midgley R.S. and Kerr D.J. (2002) Ras as a target in cancer therapy. Crit Rev Oncol Hematol 44, 109-120
4Yoon S. and Seger R. (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24, 21-44
5Haccard O. et al. (1995) Induction of Xenopus oocyte meiotic maturation by MAP kinase. Dev Biol 168, 677-682
6Haccard O. et al. (1993) Induction of metaphase arrest in cleaving Xenopus embryos by MAP kinase. Science 262, 1262-1265
7Haccard O. et al. (1993) Mitogen-activated protein kinase (MAP kinase) activation in Xenopus oocytes: roles of MPF and protein synthesis. Mol Reprod Dev 36, 96-105
8Curran K.L. and Grainger R.M. (2000) Expression of activated MAP kinase in Xenopus laevis embryos: evaluating the roles of FGF and other signaling pathways in early induction and patterning. Dev Biol 228, 41-56
9Gotoh Y. et al. (1995) Involvement of the MAP kinase cascade in Xenopus mesoderm induction. EMBO J 14, 2491-2498
10Gotoh Y. and Nishida E. (1995) Activation mechanism and function of the MAP kinase cascade. Mol Reprod Dev 42, 486-492
11Gabay L., Seger R. and Shilo B.Z. (1997) MAP kinase in situ activation atlas during Drosophila embryogenesis. Development 124, 3535-3541
12Furthauer M. et al. (2004) Fgf signalling controls the dorsoventral patterning of the zebrafish embryo. Development 131, 2853-2864
13Corson L.B. et al. (2003) Spatial and temporal patterns of ERK signaling during mouse embryogenesis. Development 130, 4527-4537
14Leichtman L.G. (1996) Are cardio-facio-cutaneous syndrome and Noonan syndrome distinct? A case of CFC offspring of a mother with Noonan syndrome. Clin Dysmorphol 5, 61-64
15Fryer A.E., Holt P.J. and Hughes H.E. (1991) The cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome: are they the same? Am J Med Genet 38, 548-551
16Neri G. and Zollino M. (1996) More on the Noonan-CFC controversy [editorial; comment]. Am J Med Genet 65, 100
17Neri G. and Opitz J.M. (2000) Heterogeneity of cardio-facio-cutaneous syndrome. Am J Med Genet 95, 144
18Tartaglia M. et al. (2003) Exclusion of PTPN11 mutations in Costello syndrome: further evidence for distinct genetic etiologies for Noonan, cardio-facio-cutaneous and Costello syndromes. Clin Genet 63, 423-426
19Noonan J.A. (1968) Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 116, 373-380
20Shaw A.C. et al. (2007) The natural history of Noonan syndrome: a long-term follow-up study. Arch Dis Child 92, 128-132
21Lin A.E. (1988) Noonan syndrome. J Med Genet 25, 64-65
22Reynolds D.J. et al. (2004) Ocular manifestations of Noonan syndrome in the pediatric patient. J AAPOS 8, 282-283
23Massarano A.A. et al. (1996) Noonan syndrome: coagulation and clinical aspects. Acta Paediatr 85, 1181-1185
24Lee D.A. et al. (2005) Psychological profile of children with Noonan syndrome. Dev Med Child Neurol 47, 35-38
25Holder-Espinasse M. and Winter R.M. (2003) Type 1 Arnold-Chiari malformation and Noonan syndrome. A new diagnostic feature? Clin Dysmorphol 12, 275
26Choong K. et al. (1999) Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol 21, 523-527
27Attard-Montalto S.P., Kingston J.E. and Eden T. (1994) “Noonan's syndrome and acute lymphoblastic leukaemia”. Med Pediatr Oncol 23, 391-392
28Bader-Meunier B. et al. (1997) Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 130, 885-889
29Moschovi M. et al. (2007) Rhabdomyosarcoma in a patient with Noonan syndrome phenotype and review of the literature. J Pediatr Hematol Oncol 29, 341-344
30Roti G. et al. (2006) Acute lymphoblastic leukaemia in Noonan syndrome. Br J Haematol 133, 448-450
31Piombo M. et al. (1993) Acute lymphoblastic leukemia in Noonan syndrome: report of two cases. Med Pediatr Oncol 21, 454-455
32Tartaglia M. et al. (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29, 465-468
33Roberts A.E. et al. (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39, 70-74
34Tartaglia M. et al. (2007) Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39, 75-79
35Pandit B. et al. (2007) Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39, 1007-1012
36Razzaque M.A. et al. (2007) Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 39, 1013-1017
37Schubbert S. et al. (2006) Germline KRAS mutations cause Noonan syndrome. Nat Genet 38, 331-336
38Zenker M. et al. (2007) Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 44, 131-135
39Tartaglia M. et al. (2002) PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70, 1555-1563
40Hof P. et al. (1998) Crystal structure of the tyrosine phosphatase SHP-2. Cell 92, 441-450
41Keilhack H. et al. (2005) Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 280, 30984-30993
42Tartaglia M. et al. (2006) Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 78, 279-290
43Fragale A. et al. (2004) Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 23, 267-277
44Niihori T. et al. (2005) Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. J Hum Genet 50, 192-202
45Araki T. et al. (2004) Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10, 849-857
46O'Reilly A.M. et al. (2000) Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Mol Cell Biol 20, 299-311
47Martinelli S. et al. (2008) Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum Mol Genet 17, 2018-2029
48Kratz C.P. et al. (2005) The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 106, 2183-2185
49Tartaglia M. et al. (2004) Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 104, 307-313
50Bentires-Alj M. et al. (2004) Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64, 8816-8820
51Chen Y. et al. (2006) Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 45, 583-591
52Loh M.L. et al. (2004) Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103, 2325-2331
53Miyamoto D. et al. (2008) Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 27, 3508-3515
54Schubbert S. et al. (2005) Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 106, 311-317
55Yoshida R. et al. (2008) Hepatoblastoma in a Noonan syndrome patient with a PTPN11 mutation. Pediatr Blood Cancer 50, 1274-1276
56Tartaglia M. et al. (2004) Paternal germline origin and sex-ratio distortion in transmission of PTPN11 mutations in Noonan syndrome. Am J Hum Genet 75, 492-497
57Friday B.B. and Adjei A.A. (2005) K-ras as a target for cancer therapy. Biochim Biophys Acta 1756, 127-144
58Niihori T. et al. (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38, 294-296
59Schubbert S. et al. (2007) Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol 27, 7765-7770
60Carta C. et al. (2006) Germline missense mutations affecting KRAS isoform B are associated with a severe noonan syndrome phenotype. Am J Hum Genet 79, 129-135
61Zenker M. et al. (2007) SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet 44, 651-656
62Swanson K.D. et al. (2008) SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes Chromosomes Cancer 47, 253-259
63Emuss V. et al. (2005) Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 65, 9719-9726
64Costello J.M. (1971) A new syndrome. N Z Med J 74, 397
65Costello J.M. (1977) A new syndrome: mental subnormality and nasal papillomata. Aust Paediatr J 13, 114-118
66Hennekam R.C. (2003) Costello syndrome: an overview. Am J Med Genet C Semin Med Genet 117, 42-48
67Rauen K.A. (2007) HRAS and the Costello syndrome. Clin Genet 71, 101-108
68Yassir W.K., Grottkau B.E. and Goldberg M.J. (2003) Costello syndrome: orthopaedic manifestations and functional health. J Pediatr Orthop 23, 94-98
69Lin A.E. et al. (2002) Further delineation of cardiac abnormalities in Costello syndrome. Am J Med Genet 111, 115-129
70Axelrad M.E. et al. (2007) Longitudinal assessment of cognitive characteristics in Costello syndrome. Am J Med Genet A 143A, 3185-3193
71Delrue M.A. et al. (2003) Costello syndrome and neurological abnormalities. Am J Med Genet A 123, 301-305
72Gregersen N. and Viljoen D. (2004) Costello syndrome with growth hormone deficiency and hypoglycemia: a new report and review of the endocrine associations. Am J Med Genet A 129, 171-175
73Stein R.I. et al. (2004) Growth hormone deficiency in Costello syndrome. Am J Med Genet A 129, 166-170
74Estep A.L. et al. (2006) HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 140, 8-16
75Kawame H. et al. (2003) Further delineation of the behavioral and neurologic features in Costello syndrome. Am J Med Genet A 118, 8-14
76Galera C. et al. (2006) Behavioral and temperamental features of children with Costello syndrome. Am J Med Genet A 140, 968-974
77Gripp K.W. (2005) Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 137, 72-77
78Gordon T. et al. (2001) Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study. Med Pediatr Oncol 36, 259-267
79Tobar A. et al. (2000) Clinical relevance of molecular diagnosis in childhood rhabdomyosarcoma. Diagn Mol Pathol 9, 9-13
80Gripp K.W. et al. (2002) Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet 108, 80-87
81Aoki Y. et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37, 1038-1040
82Gripp K.W. et al. (2006) HRAS mutation analysis in Costello syndrome: Genotype and phenotype correlation. Am J Med Genet A 140, 1-7
83Kerr B. et al. (2006) Genotype-phenotype correlation in Costello syndrome; HRAS mutation analysis in 43 cases. J Med Genet 43, 401-405
84Lo I.F. et al. (2008) Severe neonatal manifestations of Costello syndrome. J Med Genet 45, 167-171
85Schulz A.L. et al. (2008) Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin Genet 73, 62-70
86van der Burgt I. et al. (2007) Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation. J Med Genet 44, 459-462
87van Steensel M.A. et al. (2006) Recurring HRAS mutation G12S in Dutch patients with Costello syndrome. Exp Dermatol 15, 731-734
88Zampino G. et al. (2007) Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat 28, 265-272
89Denayer E. et al. (2008) Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat 29, 232-239
90Gripp K.W. et al. (2008) Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype? Am J Med Genet A 146A, 683-690
91Rauen K.A. (2006) Distinguishing Costello versus cardio-facio-cutaneous syndrome: BRAF mutations in patients with a Costello phenotype. Am J Med Genet A 140, 1681-1683
92Kerr B. et al. (2008) The diagnosis of Costello syndrome: nomenclature in Ras/MAPK pathway disorders. Am J Med Genet 146A, 1218-1220
93Sol-Church K. et al. (2006) Paternal bias in parental origin of HRAS mutations in Costello syndrome. Hum Mutat 27, 736-741
94Gripp K.W. et al. (2006) Somatic mosaicism for an HRAS mutation causes Costello syndrome. Am J Med Genet A 140, 2163-2169
95Gibbs J.B. et al. (1984) Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A 81, 5704-5708
96McGrath J.P. et al. (1984) Comparative biochemical properties of normal and activated human ras p21 protein. Nature 310, 644-649
97Sweet R.W. et al. (1984) The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature 311, 273-275
98Seeburg P.H. et al. (1984) Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312, 71-75
99Fasano O. et al. (1984) Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc Natl Acad Sci U S A 81, 4008-4012
100Newbold R.F. and Overell R.W. (1983) Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304, 648-651
101Land H., Parada L.F. and Weinberg R.A. (1983) Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596-602
102Hahn W.C. et al. (1999) Creation of human tumour cells with defined genetic elements. Nature 400, 464-468
103Levesque P. et al. (1993) Screening of human bladder tumors and urine sediments for the presence of H-ras mutations. Int J Cancer 55, 785-790
104Takahashi Y. et al. (2004) Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol 17, 660-669
105Yoo J. and Robinson R.A. (1999) H-ras and K-ras mutations in soft tissue sarcoma: comparative studies of sarcomas from Korean and American patients. Cancer 86, 58-63
106Kerr B. et al. (2003) Is the locus for Costello syndrome on 11p? J Med Genet 40, 469-471
107Blumberg B. et al. (1979) A new mental retardation syndrome with characterisitc facies, ichthyosis and abnormal hair. March of Dimes Birth Defects ConferenceChicago, Il, USA
108Reynolds J.F. et al. (1986) New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement–the CFC syndrome. Am J Med Genet 25, 413-427
109Borradori L. and Blanchet-Bardon C. (1993) Skin manifestations of cardio-facio-cutaneous syndrome. J Am Acad Dermatol 28, 815-819
110Weiss G. et al. (2004) Cutaneous manifestations in the cardiofaciocutaneous syndrome, a variant of the classical Noonan syndrome. Report of a case and review of the literature. J Eur Acad Dermatol Venereol 18, 324-327
111Wieczorek D., Majewski F. and Gillessen-Kaesbach G. (1997) Cardio-facio-cutaneous (CFC) syndrome–a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome. Clin Genet 52, 37-46
112Young T.L., Ziylan S. and Schaffer D.B. (1993) The ophthalmologic manifestations of the cardio-facio-cutaneous syndrome. J Pediatric Ophthalmol Strabismus 30, 48-52
113Grebe T.A. and Clericuzio C. (2000) Neurologic and gastrointestinal dysfunction in cardio-facio-cutaneous syndrome: identification of a severe phenotype. Am J Med Genet 95, 135-143
114Sabatino G. et al. (1997) The cardio-facio-cutaneous syndrome: a long-term follow-up of two patients, with special reference to the neurological features. Childs Nerv Syst 13, 238-241
115Herman T.E. and McAlister W.H. (2005) Gastrointestinal and renal abnormalities in cardio-facio-cutaneous syndrome. Pediatr Radiol 35, 202-205
116Chan P.C., Chiu H.C. and Hwu W.L. (2002) Spontaneous chylothorax in a case of cardio-facio-cutaneous syndrome. Clin Dysmorphol 11, 297-298
117Yoon G. et al. (2007) Neurological complications of cardio-facio-cutaneous syndrome. Dev Med Child Neurol 49, 894-899
118Van Den Berg H., Hennekam R.C.M. (1999) Acute lymphoblastic leukaemia in a patient with cardiofaciocutaneous syndrome. J Med Genet 36, 799-800
119Makita Y. et al. (2007) Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene. J Pediatr Hematol Oncol 29, 287-290
120Al-Rahawan M.M. et al. (2007) Hepatoblastoma and heart transplantation in a patient with cardio-facio-cutaneous syndrome. Am J Med Genet A 143, 1481-1488
121Rodriguez-Viciana P. et al. (2006) Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311, 1287-1290
122Wellbrock C., Karasarides M. and Marais R. (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5, 875-885
123Narumi Y. et al. (2007) Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: Overlapping clinical manifestations with Costello syndrome. Am J Med Genet A 143, 799-807
124Nava C. et al. (2007) Cardio-facio-cutaneous and Noonan syndromes due to mutations in RAS/MAPK signaling pathway: genotype/phenotype relationships and overlap with Costello syndrome. J Med Genet 44, 763-771
125Gripp K.W. et al. (2007) Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. Am J Med Genet A 143A, 1472-1480
126Wan P.T. et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867
127Garnett M.J. et al. (2005) Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20, 963-969
128Davies H. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954
129Yuen S.T. et al. (2002) Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62, 6451-6455
130Rajagopalan H. et al. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934
131Pollock P.M. et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33, 19-20
132Pearson G. et al. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22, 153-183
133Wu J. et al. (1993) Identification and characterization of a new mammalian mitogen-activated protein kinase kinase, MKK2. Mol Cell Biol 13, 4539-4548
134Brott B.K. et al. (1993) MEK2 is a kinase related to MEK1 and is differentially expressed in murine tissues. Cell Growth Differ 4, 921-929
135Alessandrini A., Brott B.K. and Erikson R.L. (1997) Differential expression of MEK1 and MEK2 during mouse development. Cell Growth Differ 8, 505-511
136Cowley S. et al. (1994) Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77, 841-852
137Mansour S.J. et al. (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966-970
138Sivaraman V.S. et al. (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99, 1478-1483
139Hoshino R. et al. (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813-822
140Bignell G. et al. (2006) Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer 45, 42-46
141Davies H. et al. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65, 7591-7595
142Hunter C. et al. (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66, 3987-3991
143Stephens P. et al. (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37, 590-592
144Estep A.L. et al. (2007) Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy. PLoS ONE 2, e1279
145Nakamura T. et al. (2007) Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest 117, 2123-2132
146Schuhmacher A.J. et al. (2008) A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest 118, 2169-2179
147Mercer K. et al. (2005) Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 65, 11493-11500
148Wojnowski L. et al. (2000) Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech Dev 91, 97-104
149Galabova-Kovacs G. et al. (2006) Essential role of B-Raf in ERK activation during extraembryonic development. Proc Natl Acad Sci U S A 103, 1325-1330
150Giroux S. et al. (1999) Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol 9, 369-372
151Belanger L.F. et al. (2003) Mek2 is dispensable for mouse growth and development. Mol Cell Biol 23, 4778-4787
152Scholl F.A. et al. (2007) Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. Dev Cell 12, 615-629
153Sebolt-Leopold J.S. and Herrera R. (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4, 937-947
154Sebolt-Leopold J.S. (2008) Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res 14, 3651-3656
155Tsai J. et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105, 3041-3046
156Senawong T. et al. (2008) Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet 17, 419-430
157Solit D.B. et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362
158Digilio M.C. et al. (2002) Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71, 389-394
159Hart T.C. et al. (2002) A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1. Am J Hum Genet 70, 943-954
160Eerola I. et al. (2003) Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 73, 1240-1249
161Cawthon R.M. et al. (1990) A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62, 193-201
162Viskochil D. et al. (1990) Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62, 187-192
163Wallace M.R. et al. (1990) Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249, 181-186
164Brems H. et al. (2007) Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 39, 1120-1126
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 44
Total number of PDF views: 87 *
Loading metrics...

Abstract views

Total abstract views: 518 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 19th November 2017. This data will be updated every 24 hours.